February 17, 2009 - Cipher Pharmaceuticals Inc. today announced that it has received tentative approval from the U.S. FDA for CIP-TRAMADOL ER, the Company's extended-release formulation of the analgesic tramadol, which is indicated for the management of moderate to moderately severe chronic pain such as osteoarthritis.
The details can be read here.
No comments:
Post a Comment